🔗 Share this article

An underground market for unlicensed weight-loss drugs is propelled by social media fitness personalities and vendors on communication apps, based on recent findings.

Experimental Drug Gaining Popularity Online

Retatrutide, which remains in clinical trials, is being advertised by online personalities for its alleged weight-reducing effects. Viewers are urged to message these accounts directly for supplier links, while also obtaining discount codes.

Thriving Trade on Messaging Platforms

Separately, a robust market exists on messaging services, where groups with numerous of members share comparison images, administration instructions and assertions of next-day UK delivery. Vendors market the drug there before redirecting customers to WhatsApp for transactions.

Understanding Retatrutide

Retatrutide is an investigational injectable created by US drugmaker Eli Lilly. The drug affects three intestinal hormones – GLP-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Preliminary studies indicate it could help individuals reduce up to 25% of their total weight. Referred to as the “triple G”, the substance is being promoted online as the successor to Ozempic.

Healthcare Professionals Voice Concerns

However, doctors and pharmacists have warned that the sale of what remains an unlicensed drug in the UK is a cause for concern and could result in individuals injecting substances of unknown origin.

Several professionals stated the popularity for the experimental drug could be connected to the increasing cost of approved weight loss products such as Mounjaro.

Legal Status and Enforcement

Marketing retatrutide on social media or messaging apps is prohibited in the United Kingdom, as it is an unapproved medication that cannot be promoted or distributed for human use under the Human Medicines Regulations 2012.

Several content creators attempt to sidestep the rules by calling to the drug as a “research chemical” or describing it as “not for human consumption”. The substance is not a restricted substance, but advertising and distribution can still violate medicines, advertising, and consumer laws, potentially leading to penalties, legal action or imprisonment.

Service Response and Content Removal

According to TikTok, the platform has removed problematic content and banned associated hashtags and search suggestions. The organization said it was dedicated to keeping the service safe and allocating resources in enhancing enforcement strategies.

Digital Marketplace Operations

Research also discovered communities with up to nine thousand participants selling retatrutide using the platform's integrated search feature, which functions like a public directory. Entering “retatrutide” instantly brings up channels with thousands of members, filled with photos of slimming results, glowing reviews and step-by-step instructions for mixing or administering at home.

Within minutes of joining one group, a seller posted WhatsApp details, where the majority of transactions occur. The vendor sent an instruction manual and promised delivery within 48 hours. When asked whether the substance was genuine, one seller said: “You can’t be sure.” Another shared a image of a supposed laboratory certificate. None asked about body mass, health issues or past usage.

Item Information and Costs

Within these communities, messages display black plastic parcels with postal service stickers, stating to include new batches. One communication stated: “It took eight of us to load them this morning.”

Customers can select between dry substance containers, mixed at home with sterile water, or ready-to-use pens typically sold at £160 for 20mg. When questioned how long a pen should last, vendors give contradictory responses ranging from a few weeks to “depends on your body”.

Platform Moderation and Security Actions

A spokesperson for Telegram said it actively moderated harmful content on its service including material that promoted the “misuse of controlled medications”. The organization noted that it eliminated “millions of pieces of harmful content each day”.

Medical Expert Cautions

“People are injecting materials they cannot confirm. Although the research behind this drug is valid, these digital versions may not contain what they claim,” said Jason Murphy, the head of pharmacy at Chemist4U.

Dr Crystal Wyllie of an online medical service connected the surge in interest to recent price rises for authorized slimming medications such as Mounjaro. “With prices increasing, patients are turning to social media. But fake treatments are extremely risky. You cannot know what’s contained or whether the conditions they were produced in was clean,” she explained.

Her staff has already encountered patients harmed by self-injection from unconfirmed suppliers. “We recognize the disappointment, but buying from Telegram or communication platforms is taking chances with your health,” said Wyllie. “These materials could be contaminated or incorrectly dosed.”

Producer Statement

A representative from the pharmaceutical company stated the substance was in third stage clinical trials and had not been evaluated or approved by any government authority globally. “Therefore at this point no one can market [it] for personal consumption,” they said, noting that any product “misleadingly claiming itself as a company experimental product not yet approved … may subject patients to possibly significant medical dangers”.